具有调节剂量和快速释放的3D打印prednisolone酸,用于治疗炎症性肠病
L I Kocabas1, S Ayyoubi1, M Tajqurishi1
1Division of Pharmaceutics, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht 3584 CG, the Netherlands.
International journal of pharmaceutics
|December 2, 2023
概括
三维 (3D) 打印使个性化儿科医学成为可能,创建具有可调剂量和快速释放炎症性肠病药物的普雷尼索隆假药. 这项技术为儿童提供量身定制的治疗方法,改善药物管理和疗效.
科学领域:
- 制药技术 制药技术 制药技术
- 材料科学 材料科学 材料科学
- 儿科医学 儿科医学
背景情况:
- 既定药物往往缺乏儿科专用配方,导致管理和剂量挑战.
- 三维 (3D) 打印为个性化药物复合提供了一种新的解决方案,特别是对于儿科直肠制剂.
研究的目的:
- 为了研究3D打印带有普雷尼索隆酸盐的假药剂的材料要求.
- 为了实现调节剂量和快速释放药物,用于儿科炎性肠病治疗.
主要方法:
- 沉积建模 (FDM) 3D打印被用来创建支架.
- 配方包括普雷迪尼索隆酸 (PSP),基基纤维素 (HPC) 和曼尼托尔作为孔形成剂.
- 进行了溶解研究和印刷,使用不同的灌装密度和尺寸.
主要成果:
- 增加的曼尼托尔含量提高了PSP释放率,在30分钟内达到90%的释放率,其中48%是曼尼托尔.
- 用48%的曼尼托尔3D打印的支架允许调节剂量 (6-30毫克PSP),而不会显著改变溶解动力学.
- 打印参数如灌装密度和尺寸被调整以控制药物剂量.
结论:
- 3D打印有助于自动组合个性化的儿科直肠假药.
- 这项技术允许精确控制药物剂量和释放特征,确保治疗疗效.
- 3D打印的假药器代表了量身定制的儿科药物治疗的有希望的方法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Constipation-Predominant IBS
179
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
179
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182


